Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 8/20 | 0.60 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.55 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.55 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.55 |
| ▸ | CTSB | P07858 | 2/20 | 0.55 |
| ▸ | NPY1R | P25929 | 1/20 | 0.53 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
| ▸ | NPY4R | P50391 | 1/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omiganan SCHEMBL29410943 | 0.99 | CXCR4 (0.59) | CXCR4KISS1RNTSR2NTSR1SORT1 | |
| SCHEMBL28202049 | 0.99 | CXCR4 (0.60) | CXCR4KISS1RNTSR2NTSR1SORT1 | |
| SCHEMBL29675079 | 0.99 | CXCR4 (0.60) | CXCR4KISS1RNTSR2NTSR1SORT1 | |
| SCHEMBL29674929 | 0.96 | CXCR4 (0.59) | CXCR4KISS1ROPRM1OPRK1 | |
| SCHEMBL29675119 | 0.96 | CXCR4 (0.59) | CXCR4KISS1ROPRM1OPRK1 | |
| SCHEMBL29412263 | 0.95 | CXCR4 (0.61) | CXCR4KISS1RNTSR2NTSR1SORT1 | |
| SCHEMBL30273393 | 0.94 | CXCR4 (0.61) | CXCR4KISS1RNTSR2NTSR1SORT1 | |
| SCHEMBL29443798 | 0.92 | CXCR4 (0.60) | CXCR4KISS1RNTSR2NTSR1SORT1 | |
| SCHEMBL29367784 | 0.89 | NTSR2 (0.62) | CXCR4NTSR2NTSR1SORT1OPRM1 | |
| SCHEMBL30498028 | 0.88 | OPRM1 (0.65) | OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377186-B2 | Antimicrobial biopolymer compositions, methods of synthesis, and applications of use | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-08-05 | — | — | US | claimed |
| US-12329822-B2 | Antimicrobial tailored chitosan | UNIVERSITÉ DE GENVE (CH) | 2025-06-17 | — | — | US | claimed |
| WO-2025106551-A1 | HYDROGEL COMPOSITIONS COMPRISING SYNERGISTIC ANTIMICROBIAL PEPTIDES (AMPS) AND METHODS OF MAKING SAME | ROWAN UNIVERSITY (US) | 2025-05-22 | — | — | WO | claimed |
| CN-119287546-A | Preparation method and application of biofouling-resistant protein fiber material for extracting uranium from seawater | 平顶山学院 | 2025-01-10 | — | — | CN | claimed |
| WO-2024125320-A1 | USE OF DIPYRIDAMOLE AND PREPARATION THEREOF IN PREVENTING AND TREATING ATOPIC DERMATITIS | 智泽童康(广州)生物科技有限公司 | 2024-06-20 | — | — | WO | claimed |
| EP-3965887-B1 | ANTIMICROBIAL CHITOSAN | UNIV GENEVE (CH) | 2024-02-28 | — | — | EP | claimed |
| US-20220193244-A1 | ANTIMICROBIAL TAILORED CHITOSAN | UNIVERSITE DE GENEVE (CH) | 2022-06-23 | — | — | US | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| EP-3717053-B1 | METHOD AND DEVICES FOR SIGNIFYING SCRUBBING ACTION | CARE FUSION 2200 INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260085341-A1 | Using Multiple Heteroresistance to Guide Combination Antimicrobial Regimens | UNIV EMORY (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| EP-3947695-A1 | MUT- METHYLOTROPHIC YEAST | Universität für Bodenkultur Wien (AT) | 2022-02-09 | — | — | EP | disclosed |
| CN-114026239-A | MUT-methanol nutritional yeast | 维也纳自然资源与生命科学大学 | 2022-02-08 | — | — | CN | disclosed |
| CN-114026213-A | Continuous blade type impeller | 龙沙有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-11236520-B2 | Customizable facility | LONZA LTD (CH) | 2022-02-01 | — | — | US | disclosed |
| EP-3942014-A1 | CONTINUOUS BLADE IMPELLER | Lonza Ltd. (CH) | 2022-01-26 | — | — | EP | disclosed |
| CN-102167731-B | Method for preparing omiganan through solid phase peptide synthesis | ZHOU YIMING | 2013-01-23 | — | — | CN | disclosed |
| CN-102167731-A | Method for preparing omiganan through solid phase peptide synthesis | YIMING ZHOU | 2011-08-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | CXCR4 1755/4885KISS1R 586/4885NTSR2 54/4885 |
| US-20260085341-A1 | Using Multiple Heteroresistance to Guide Combination Antimicrobial Regimens | Q6ZSR9, AMPD2, AMPD1 | CXCR4 3761/4885KISS1R 4278/4885NTSR2 898/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | CXCR4 801/4885KISS1R 297/4885NTSR2 114/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | CXCR4 1345/4885KISS1R 3677/4885NTSR2 315/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | CXCR4 1146/4885KISS1R 2445/4885NTSR2 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.